The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when introducing the fixed-dose combination (FDC) of paediatric abacavir/lamivudine/ dolutegravir (pALD). Specifically, this brief aims to inform the transition from pDTG + pABC/3TC to pALD.

Click here to access the brief.